A comparison of the three year course between chronic depression and depression with multiple vs. few prior episodes by Humer, Elke et al.
Contents lists available at ScienceDirect
Psychiatry Research
journal homepage: www.elsevier.com/locate/psychres
A comparison of the three year course between chronic depression and
depression with multiple vs. few prior episodes
Elke Humera, Krisztina Kocsis-Bogara, Thomas Bergerb, Johanna Schröderc, Christina Späthd,
Björn Meyere,f, Steffen Moritzc, Wolfgang Lutzg, Thomas Probsta,1, Jan Philipp Kleind,1,⁎
a Department for Psychotherapy and Biopsychosocial Health, Danube University Krems, Krems, Austria
bDepartment of Clinical Psychology and Psychotherapy, University of Bern, Bern, Switzerland
c Department of Psychiatry and Psychotherapy, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany
dDepartment of Psychiatry and Psychotherapy, Lübeck University, 23538 Lübeck, Germany
e Research Department, Gaia AG, Hamburg, Germany
fDepartment of Psychology, City, University of London, United Kingdom
g Department of Psychology, University of Trier, Trier, Germany
A R T I C L E I N F O
Keywords:
Dysthymic disorder
Mood disorders
Web-based
Quality of life
A B S T R A C T
This study tested the hypothesis that chronic depression (CD) is more similar to depression with multiple prior
episodes (ME) than to depression with few prior episodes (FE). Data from participants (n = 1013) with mild to
moderate depressive symptoms (Patient Health Questionnaire [PHQ-9] score 5 – 14) who took part in a ran-
domized control trial of an internet intervention for depression (EVIDENT trial) were re-analyzed. The MINI-
interview was conducted to diagnose CD (n = 376). If CD was not diagnosed, the self-reported number of
depressive episodes was used to categorize participants as having episodic depression with up to five (FE,
n = 422) or more than five (ME, n = 215) prior episodes. Over a three-year period, participants were assessed
repeatedly regarding the course of depression (PHQ-9, QIDS), quality of life (SF-12) and therapeutic progress
(FEP-2). At baseline, most scores were different between CD and FE but comparable between CD and ME. Time
to remission did not differ between CD and ME but was longer in CD compared to FE. Results suggest that ME
closely resembles CD and that CD differs from FE.
1. Introduction
Major depressive disorder is one of the most frequent mental dis-
orders with a lifetime prevalence of 15% (Wittchen et al., 2011).
Chronic depression (CD) develops in approximately 20 to 30% of de-
pressed individuals (Jobst et al., 2016; Murphy and Byrne, 2012). De-
finitions of CD vary among diagnostic manuals and studies (see
Jobst et al., 2016). In DSM-5 the diagnostic entity “persistent depressive
disorder” was introduced as a new category that aims to combine
dysthymic disorder (including double depression) and chronic major
depression (American Psychiatric Association, 2013), as these forms of
depression could not be differentiated satisfactorily based on their
symptomatology and course, and because both illnesses respond to the
same treatments (Ildirli et al., 2015; Jobst et al., 2016). The current
ICD-10 (WHO, 2010) does not offer a distinct diagnosis of CD in a si-
milar way as DSM-5, with only the category dysthymia corresponding
to CD.
Currently, “chronicity” is defined by the duration of depressive
symptoms, with a threshold of two years (American Psychiatric
Association, 2013). Some clinicians, however, also label highly re-
current depression as “chronic”. For example, Barnhofer et al. (2009)
combined patients with more than three episodes and patients with CD
in their trial on mindfulness-based cognitive therapy for CD. Research
results indeed indicate similarities between recurrent depression and
CD. A chronic course is predicted by similar risk factors as a recurrent
course of depression (Hoertel, 2017; ten Have et al., 2018). Even more
similarities can be found between CD and depression with multiple
prior episodes (ME). CD is characterized by more psychiatric co-
morbidities, a more difficult treatment course, more submissive and
hostile interpersonal styles, an earlier onset of depression, and more
childhood adversities than non-chronic depression (Bird et al., 2018;
Klein et al., 2015; Köhler et al., 2019; Nelson et al., 2017), whereby the
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latter two (onset, childhood adversities) are also characteristics of ME
compared to depression with few prior episodes (FE) (Bockting et al.,
2005; Ma and Teasdale, 2004).
Previous research suggests that CD shows more similarities to ME
than to FE; however, to the best of our knowledge individuals with CD
have never been directly compared to those with ME vs. FE. Using data
from a randomized controlled trial, we compared these three groups
(CD, ME and FE) with regard to differences in clinical variables (de-
pressive symptoms, quality of life, well-being, symptom distress, in-
terpersonal problems, and incongruence) at baseline (cross-sectional)
and over the course of three years (longitudinal). Based on the litera-
ture cited above, we hypothesized that participants with the diagnosis
of CD closely resemble (at baseline and over the course of three years)
those with ME but differ from those with FE.
2. Methods
This study is based on a multicenter (five sites in Germany) ran-
domized, controlled and assessor-blinded trial comparing the internet-
based intervention “Deprexis” with the control condition care-as-usual
(CAU). The trial was conducted in compliance with the Declaration of
Helsinki and approved by the Ethics Committee of the German
Psychological Association (SM 04_2012) and registered with
ClinicalTrials.gov (NCT01636752). The full protocol (Klein et al.,
2013), results regarding the effectiveness of the intervention
(Klein et al., 2016, 2017b) as well as results for moderators of treatment
effects (Probst et al., 2020) have been published previously.
2.1. Participants
The recruitment process has been described in detail elsewhere
(Klein et al., 2017a). Inclusion criteria were age between 18 and 65,
internet access, the ability to communicate in German, and self-re-
ported mild to moderate depressive symptoms on the Patient Health
Questionnaire-9 (PHQ-9; (Kroenke et al., 2001). Mild depressive
symptoms were defined as PHQ-9 scores between 5 and 9, whereas
moderate depressive symptoms were PHQ-9 scores from 10 to 14. Ex-
clusion criteria were acute suicidality, lifetime diagnosis of bipolar
disorder or schizophrenia (Klein et al., 2016; 2017b).
In total, n = 1013 participants (Fig. 1) were randomized (ratio 1:1)
into the control condition (care-as-usual, CAU) or the intervention
condition (CAU plus Deprexis). Randomization into the intervention or
control condition was stratified by PHQ-9 (PHQ-9 < 10 vs. PHQ-
9 ≥ 10), as participants with PHQ-9 < 10 (mild depressive symptoms)
received unguided Deprexis and participants with PHQ-9 ≥ 10 (mod-
erate depressive symptoms) received guided Deprexis. Based on the
Mini International Neuropsychiatric Interview (MINI), a structured in-
terview conducted at baseline (see measures), participants were cate-
gorized as having dysthymia or not. Dysthymia was diagnosed in
n = 376 (37%) participants (CD group). Among CD-participants, 198
(53%) reported a history of up to five depressive episodes and 178
(47%) of more than five previous episodes. In 115 CD-participants
dysthymia was accompanied by a current major depressive disorder,
thus meeting the criteria of double depression according to DSM-IV
(American Psychiatric Association, 1994). Participants without a MINI
dysthymia diagnosis were categorized according to their self-reported
number of depressive episodes as either non-chronic with a history of
up to five depressive episodes (few episodes; FE group, n = 422, 42%)
or non-chronic with more than five depressive episodes (multiple prior
episodes; ME group, n = 215, 21%).
2.2. Intervention
All participants were permitted to use any form of treatment, in-
cluding medication and psychotherapy for depression or other condi-
tions. This constituted CAU. Participants in the control condition
received solely CAU during the first 12-months. Following a naturalistic
design approach, CAU was not influenced by the investigators but
monitored during the course of the study (Klein et al., 2017). The
control group participants were offered access to a psychological in-
ternet intervention (Deprexis) 12 months after the baseline assessment.
Participants in the intervention condition received CAU as well as
immediate access to the internet intervention (Deprexis). Immediately
after randomization, they were offered access to the 12-week CBT-
based internet intervention Deprexis. Briefly, the Deprexis program
consists of ten modules, including therapeutic techniques such as cog-
nitive restructuring, behavioral activation, acceptance and mindfulness,
relaxation exercises, problem-solving, and positive psychology inter-
ventions (Meyer et al., 2009).
Details on the treatment utilization (antidepressant medication,
inpatient psychiatric treatment, outpatient psychiatric treatment) in the
CAU as well as Deprexis group have been reported previously
(Klein et al., 2016, 2017b) and details on adherence to Deprexis were
published by Fuhr et al. (2018).
2.3. Measures
2.3.1. Mini International Neuropsychiatric Interview (MINI)
The MINI 6.0 (Sheehan et al., 1998) is a structured interview to
assess DSM-IV (American Psychiatric Association, 1994) and ICD-10
(World Health Organization, 2010) psychiatric disorders. The MINI was
administered by trained raters via telephone. Raters were mostly de-
gree-educated psychologists but also included advanced graduate stu-
dents majoring in psychology or medicine. Before they were permitted
to rate trial participants, raters completed face-to-face training and
were required to demonstrate adequate interrater reliability on an
audiotaped interview.
2.3.2. Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is a self-administered version of the PRIME-MD diag-
nostic instrument for common mental disorders (Kroenke et al., 2001).
The nine items known as PHQ-9 represent the depression module; each
item is rated on a 4-point Likert-scale from “0″ (not at all) to “3″ (nearly
every day). The PHQ-9 score can thus range between 0 and 27, and
remission can be defined as a total score below the threshold for mild
depressive symptoms (PHQ < 5) (Nierenberg and DeCecco, 2001). The
PHQ-9 has been shown to be a valid and reliable measure of depression
that is sensitive to change (Löwe et al., 2004; Nierenberg and
DeCecco, 2001). The PHQ-9 represented the primary outcome and was
administered at baseline and at 14 follow-ups: 3-months, monthly from
4 to 12 months, 18-months, 24-months, 30-months, 36-months). In our
sample, internal consistency was good (α=0.80 – 0.85).
2.3.3. Quick Inventory of Depressive Symptomatology (QIDS)
The PHQ-9 was complemented by the clinician-rated version of the
QIDS via telephone interviews. Depressive symptom severity is assessed
by 16 items referring to the last seven days, focusing on the nine DSM-
IV criterion symptom domains measuring psychological as well as so-
matic symptoms (Rush et al., 2003). The QIDS was applied at baseline
and at two follow-ups: 3-months and 12-months. The internal con-
sistency of QIDS was satisfactory (α = 0.75).
2.3.4. Short-Form Health Survey (SF-12)
The SF-12 is an abbreviated version of the 36-item “Short-Form
Health Survey”, containing two subscales measuring physical and
mental aspects of health-related quality of life (Ware et al., 1996). The
SF-12 is a self-report measure rating the presence and severity of phy-
sical and psychological impairment over the course of the last four
weeks. The subscale scores range from 0 to 100, where higher scores
indicate higher levels of health. The SF-12 was administered at baseline
and seven follow-ups: 3-months, 6-months, 12-months, 18-months, 24-
months, 30-months, 36-months.
E. Humer, et al. Psychiatry Research 291 (2020) 113235
2
2.3.5. Questionnaire for the Evaluation of Psychotherapeutic Progress-2
(FEP-2)
The FEP-2 was developed as a measure of therapeutic progress,
which has been shown to be change-sensitive as well as reliable
(Lutz et al., 2009; Lutz and Böhnke, 2008). The instrument can also be
used as a broad symptom measure covering the following four dimen-
sions: well-being, symptom distress, interpersonal problems and in-
congruence with respect to approach and avoidance goals. The FEP-2
Fig. 1. Flow Diagram of Study. Deprexis: internet intervention for depression. CD: chronic forms of depression. ME: more than five depressive episodes. FE: up to
five depressive episodes. PHQ-9: Patient Health Questionnaire-9. QIDS: Quick Inventory of Depressive Symptomatology. SF-12: Short-Form Health Survey. FEP:
Questionnaire for the Evaluation of Psychotherapeutic Progress-2.
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consists of 40 items that are rated on a 5-point Likert-type scale, with
higher scores indicating higher impairment. Reliability is high for the
global scale (Cronbach α = 0.96; Retest between rtt = 0.69–0.77) and
sensitivity to change has been demonstrated (Lutz et al., 2009). The
FEP-2 was administered at baseline and seven follow-ups: 3-months, 6-
months, 12-months, 18-months, 24-months, 30-months, 36-months.
2.4. Statistical analyses
Statistical analyses were conducted with SPSS version 25 (Inc,
Chicago, IL, USA). All tests were performed two-tailed and the sig-
nificance value was set to p < 0.05. To evaluate differences in socio-
demographic characteristics, univariate ANOVAs and chi-square-tests
were conducted. Bonferroni corrections were applied for the pairwise-
post-hoc tests. To assess whether the three depression groups (CD, ME,
FE) differ at baseline and over time in the outcome variables (depres-
sive symptoms, quality of life, well-being, symptom distress, inter-
personal problems, and incongruence), linear multilevel models were
conducted. One multilevel model was conducted for each outcome
variable (PHQ-9, QIDS, SF-12, and FEP-2 scales), as the number of re-
peated assessments differed among the dependent variables (i.e., PHQ-
9: 15 time points; FEP-2, SF-12: 8 time points; QIDS: 3 time points) as
described above. All models had two-levels (repeated measures nested
within individuals) and were performed with the full maximum like-
lihood method. Fixed effects were time and depression group (CD, ME,
FE with CD being the reference) as well as the interaction between time
and depression group. The time variable was calculated for each par-
ticipant individually as days of the follow-up assessment after baseline
assessment (coded as 0), since the timing of the follow-up assessments
varied between participants. As random term, the random intercept was
included, the random slope was not added as the models did not con-
verge with a random intercept and a random slope.
We also conducted a time to event analysis to evaluate differences
between the depression groups (CD, ME, FE with CD being the re-
ference) in time to remission from depressive symptoms as measured
with the PHQ-9 (the first time a PHQ-9 score < 5 was reached was
defined as the onset of remission). Participants who did not achieve
remission within 36 months or dropped out were censored. No missing
data were substituted in the analysis. The Kaplan-Meier method was used
to estimate time to remission (in days) and differences among the three
depression groups were compared using the log-rank, Breslow and
Taron-Ware tests.
The multilevel models and the event analysis were conducted for
the total sample as well as for the intervention (Deprexis) and control
condition (CAU) separately. This was done to explore whether the re-
sults for the total sample can be replicated in both conditions.
3. Results
3.1. Baseline comparisons between the three depression groups
3.1.1. Sociodemographic variables
Significant differences among the three depression groups were
observed in age (F(2, 1012) = 3.65, p= 0.026) and gender (χ2 = 8.18,
p = 0.017) but not in marital status and education (Table 1). Post-hoc
tests for age showed that the CD group was older than the FE group
(p = 0.021). Importantly, no age differences emerged between ME and
FE (p = 0.918) ruling out the possibility that ME participants devel-
oped more episodes than FE participants because of their older age.
3.1.2. Outcome variables at baseline
CD vs. ME: For the total sample (Tables 2-4), the intercepts did not
differ between the CD and the ME group in depression severity (PHQ-9
and QIDS), the SF-12 mental component, and the FEP-2 scales. Solely
for the SF-12 physical component (p = 0.019), a significant difference
towards stronger impairment in CD was observed at baseline. However,
when the analysis was conducted for the CAU and Deprexis condition
separately (Supplemental Tables 1–3), the intercepts of all dependent
variables did not differ between CD and ME.
CD vs. FE: The intercepts of all investigated variables differed, with
a stronger impairment in CD (p < 0.001) for the total sample (Tables 2-
4). This was also the case when running the analysis separately for the
Deprexis and the CAU condition (Supplemental Tables 1–3).
3.2. Comparisons between the three depression groups in trajectories of
outcome variables over the 3-year observation period
The time courses of the primary outcome, as well as the secondary
outcome variables, are reflected by the estimates for the fixed effect
time (slope) summarized in Tables 2-4 for the total sample. For all
analyzed dependent variables, no differences were observed between
CD and ME as well as between CD and FE.
Separate statistical analyses of the two treatment conditions
(Supplemental Table 1–3) were in accordance with the analysis of the
total sample, except for differences in the control group sample be-
tween CD and FE in the FEP-2 scales interpersonal problems
(p = 0.036), incongruence (p = 0.028) and the total score (p = 0.044).
The slopes were more positive in FE compared to CD in these variables
and this means less improvement over time for FE compared to CD.
3.3. Time to remission
The three depression groups differed in the estimated time to onset
of remission from depressive symptoms (PHQ-9) within the three years
observation period after randomization (log rank χ2 = 22.84, p <
0.001; Breslow χ2 = 24.97, p < 0.001, Taron-Ware χ2 = 24.60, p <
0.001). The CD group (estimated M = 723 days (± 29.12), lower
bound: 666 days, upper bound: 780 days) and the ME group (estimated
M = 767 days (± 46.84), lower bound: 675 days, upper bound: 859
days) showed an approximately similar time to onset of remission (log
rank χ2 = 0.324, p = 0.570; Breslow χ2 = 0.328, p < 0.567, Taron-
Ware χ2 = 0.332, p < 0.564), whereas the estimated mean symptom
duration in group FE was significantly shorter than in CD (M = 555
days (± 27.79), lower bound: 500 days, upper bound: 609 days; log
rank χ2 = 10.350, p < 0.001; Breslow χ2 = 11.068, p < 0.001, Taron-
Ware χ2 = 11.006, p < 0.001; Fig. 2).
Stratifying the total sample according to condition, differences re-
garding the duration of the depressive symptoms among the three de-
pression groups remained significant in both conditions (Deprexis: log
rank χ2 = 6.21, p= 0.045; Breslow χ2 = 5.83, p= 0.054, Taron-Ware
χ2 = 6.21, p = 0.045; CAU: log rank χ2 = 18.46, p < 0.001; Breslow
χ2 = 23.46, p < 0.001, Taron-Ware χ2 = 21.46, p < 0.001). Thus,
results for the depression groups in the two subsamples concurred with
those observed for the total sample (Supplemental Fig. 1–2).
4. Discussion
The current study was conducted to examine whether participants
with CD resemble those with ME but differ from those with FE.
At baseline, significant differences emerged between CD and FE in
all investigated outcome variables, but only one significant difference
was observed between CD and ME (physical quality of life) in the total
sample. Regarding the trajectories over three years, CD and ME did not
differ in any of the parameters, whereas CD and FE differed in several
outcome variables in the CAU condition. Furthermore, time to remis-
sion from depressive symptoms was similar in CD and ME but differed
between CD and FE.
In summary, we found more differences between CD and FE than
between CD and ME, although more than half of CD-participants (53%)
had a history of up to five depressive episodes as had the FE group. Yet,
we also observed a difference regarding physical aspects of health-re-
lated quality of life at baseline between CD and ME. These results
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provide partial support for our hypothesis.
Conventionally, several factors are examined when trying to vali-
date a diagnostic category: antecedent validators (e.g. risk factors),
concurrent validators (e.g. symptom similarity) and predictive valida-
tors (e.g. clinical course and treatment response). Our results provide
Table 1
Sociodemographic characteristics of the depression groups at baseline. Frequency and percentage.
CD ME FE Statistics p
N (%) 376 (37.1%) 215 (21.2%) 422 (41.7%)
Age, mean (SD) 44.0 (10.7) 42.7 (10.4) 41.9 (11.5) F (2, 1012) = 3.65 0.026
Gender χ2 = 8.18 0.017
Male 111 (29.5%) 55 (25.6%) 152 (36.0%)
Female 265 (70.5%) 160 (74.4%) 270 (64.0%)
Marital status χ2 = 16.81 0.079
Married 154 (41.0%) 92 (42.8%) 179 (42.4%)
Married, but living separated 14 (3.7%) 3 (1.4%) 11 (2.6%)
Single 85 (22.6%) 49 (22.8%) 113 (26.8%)
In relationship 63 (16.8%) 50 (23.3%) 76 (18.0%)
Divorced 54 (14.4%) 21 (9.8%) 40 (9.5%)
Widowed 6 (1.6%) 0 (0%) 3 (0.7%)
Educational level χ2 = 8.64 0.734
No graduation 1 (0.3%) 1 (0.5%) 1 (0.2%)
Lower secondary 22 (5.9%) 13 (6.0%) 18 (4.3%)
Middle secondary 95 (25.3%) 52 (24.2%) 96 (22.7%)
Higher secondary 67 (17.8%) 37 (17.2%) 68 (16.1%)
Highest secondary 182 (48.4%) 110 (51.2%) 228 (54.0%)
Other 9 (2.4%) 2 (0.9%) 11 (2.6%)
Abbreviations: CD: chronic forms of depression. ME: more than five depressive episodes. FE: up to five depressive episodes. N: sample size. SD: standard deviation.
χ2: chi square.
Table 2
Estimates of the multilevel model with PHQ-9 and QIDS as dependent variable.
Parameter Estimate SE df t p
PHQ-9
Intercept (CD) 9.44 0.17 1261.87 54.57 < 0.001
ME −0.24 0.29 1275.35 −0.83 0.408
FE −1.35 0.24 1276.53 −5.66 < 0.001
Time (CD) −0.00169 0.00020 7658.35 −8.28 < 0.001
Time x ME 0.00050 0.00035 7677.36 1.44 0.149
Time x FE −0.00023 0.00028 7674.98 −0.82 0.413
QIDS
Intercept (CD) 8.94 0.20 1529.51 44.06 < 0.001
ME −0.22 0.34 1527.49 −0.65 0.518
FE −1.28 0.28 1538.13 −4.56 < 0.001
Time (CD) −0.00495 0.00078 1496.45 −6.38 < 0.001
Time x ME −0.00146 0.00129 1500.00 −1.13 0.258
Time x FE −0.00194 0.00107 1504.24 −1.81 0.071
Abbreviations: QIDS: Quick Inventory of Depressive Symptomatology. PHQ-9:
Patient Health Questionnaire-9. SE: standard error. CD: chronic forms of de-
pression. ME: more than five depressive episodes. FE: up to five depressive
episodes.
Table 3
Estimates of the multilevel model with SF-12 as dependent variable.
Parameter Estimate SE df t P
Physical component
Intercept (CD) 45.92 0.43 1236.98 105.95 < 0.001
ME 1.69 0.72 1235.27 2.35 0.019
FE 3.06 0.60 1237.51 5.15 < 0.001
Time (CD) −0.00027 0.00046 3875.94 −0.58 0.562
Time x ME −0.00119 0.00079 3886.23 −1.51 0.130
Time x FE −0.00010 0.00064 3873.44 −0.16 0.874
Mental component
Intercept (CD) 33.01 0.45 1499.27 73.40 < 0.001
ME 1.19 0.74 1498.10 1.59 0.111
FE 3.29 0.62 1497.85 5.33 < 0.001
Time (CD) 0.00702 0.00061 4106.88 11.50 < 0.001
Time x ME −0.00128 0.00104 4126.60 −1.24 0.216
Time x FE 0.00082 0.00084 4103.22 0.97 0.333
Abbreviations: SF-12: Short-Form Health Survey. SE: standard error. CD:
chronic forms of depression. ME: more than five depressive episodes. FE: up to
five depressive episodes.
Table 4
Estimates of the multilevel model with FEP-2 as dependent variable.
Parameter Estimate SE df t p
Well-being
Intercept (CD) 3.43 0.03 1461.96 102.82 < 0.001
ME −0.09 0.06 1462.63 −1.56 0.119
FE −0.32 0.05 1465.64 −6.89 < 0.001
Time (CD) −0.00038 0.00004 4138.32 −8.62 < 0.001
Time x ME 0.00011 0.00007 4155.17 1.47 0.142
Time x FE −0.00003 0.00006 4141.49 −0.51 0.611
Complaints
Intercept (CD) 2.80 0.03 1395.67 91.90 < 0.001
ME −0.08 0.05 1394.49 −1.53 0.129
FE −0.25 0.04 1399.23 −6.01 < 0.001
Time (CD) −0.00036 0.00004 4088.43 −9.35 <0.001
Time x ME 0.00009 0.00007 4102.03 1.33 0.184
Time x FE 0.000001 0.00005 4091.46 0.01 0.990
Interpersonal problems
Intercept (CD) 2.57 0.03 1223.82 87.59 < 0.001
ME −0.09 0.05 1222.64 −1.82 0.069
FE −0.20 0.04 1226.74 −4.99 < 0.001
Time (CD) −0.00021 0.00003 3922.78 −7.06 < 0.001
Time x ME 0.00002 0.00005 3930.18 0.34 0.735
Time x FE 0.00003 0.00004 3925.18 0.73 0.463
Incongruence
Intercept (CD) 3.03 0.03 1345.33 99.20 < 0.001
ME −0.05 0.05 1345.67 −1.04 0.301
FE −0.27 0.04 1348.76 −6.34 < 0.001
Time (CD) −0.00032 0.00004 4044.45 −8.77 < 0.001
Time x ME 0.00003 0.00006 4057.52 0.53 0.593
Time x FE 0.00001 0.00005 4047.33 0.26 0.797
Total
Intercept (CD) 2.90 0.03 1349.09 107.40 < 0.001
ME −0.08 0.04 1349.40 −1.68 0.093
FE −0.25 0.04 1352.51 −6.77 < 0.001
Time (CD) −0.00031 0.00003 4043.13 −9.60 < 0.001
Time x ME 0.00006 0.00005 4055.76 1.03 0.301
Time x FE 0.00001 0.00004 4045.96 0.14 0.889
Abbreviations: FEP-2: Questionnaire for the Evaluation of Psychotherapeutic
Progress-2. SE: standard error. CD: chronic forms of depression. ME: more than
five depressive episodes. FE: up to five depressive episodes.
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concurrent (similar but not identical baseline symptoms) and predictive
validators (similar three-year course) suggesting that patients with ME
and CD belong to the same category. The studies by Bockting et al.
(2005) and Ma and Teasdale (2004) provide antecedent evidence
(childhood adversity and age of onset), suggesting that the ME and FE
categories might be separate. Unfortunately, we were unable to com-
pare participants with CD and ME with respect to these or other ante-
cedent validators. Therefore, our results must be replicated and ex-
tended before firm conclusions can be drawn regarding the diagnostic
validity and utility of a “frequent episode” category.
Altogether, the current findings emphasize the need for further re-
finement of the definition of CD, to improve treatments for those who
have developed a more protracted course of the disorder but are cur-
rently not considered as patients with CD. According to our study an
extension of the definition of chronic forms of depression including
those patients with a high number of previous depressive episodes,
should be considered and evaluated in future studies.
4.1. Strengths and limitations
Several strengths and limitations should be noted. The first strength
of this study is the relatively long observation period of three-years,
which allowed us to study whether the outcome trajectories differed
among the three depression groups. A second strength is the large
sample size, which allowed us to create relatively large subsamples
with different depression forms. A third strength concerns the fact that
participants were recruited from a broad array of clinical and non-
clinical settings, which enhances external validity. A fourth strength is
the broad generalizability of our findings as the trial's inclusion criteria
were broad, allowing any form of concomitant treatment. A fifth
strength is that all statistical analyses were not only conducted for the
total sample, but also for the intervention and control group separately.
These additional analyses largely confirmed that the results for the total
sample are replicable in both conditions. A final strength is that the
diagnosis of dysthymia and the diagnosis of current depression (MINI)
as well as depression severity (QIDS) were ascertained by trained
clinical raters.
There are also limitations to consider when interpreting the results.
The first and major limitation of the study is that CD was assessed with
an interview, whereas the differentiation between ME and FE was based
on self-reports. Recall bias regarding the illness course could have led to
false classifications, at least in some participants (Andrews et al., 1999).
Using the same method to assess CD, ME, and FE would have been
ideal. A second limitation is that the differentiation between ME and FE
was based on lifetime history of more or up to five episodes. In contrast,
other studies used different cut-offs, such as three (Ma and
Teasdale, 2004), four (Bockting et al., 2009), or five (Bockting et al.,
2005) previous episodes. To avoid the problem of selecting a cut-off
score to dichotomize the sample into those with multiple vs. few prior
episodes, continuous scoring of the episodes should be used in future
research, which should also apply validated clinical interviews to assess
the number of previous depressive episodes. These future studies should
also include a detailed assessment of the subtypes of CD, as the chronic
forms investigated here included dysthymia and double depression only
(the MINI interview evaluated current major depression as well as
dysthymia but no other depressive disorders). Therefore, we do not
know whether and how many participants met the criteria of persistent
major depressive episode, intermittent major depressive episode with
current episode, or intermittent major depressive episode without
current episode as defined in DSM-5. It might be that the chronic forms
of depression evaluated here (dysthymia and double depression) more
closely resemble ME than FE, but other forms of CD might not show the
same pattern. Another shortcoming is related to the lack of biological
samples due to the online study design, e. g., cortisol levels (also in
response to stimulus) might help to differentiate the groups. Moreover,
there were age and gender differences between the groups. Including
gender and age as moderators in further studies would be interesting to
see if results are comparable for women and men and across age groups.
A further limitation of the study is that generalizability is limited by the
mild to moderate symptom severity range in our sample; thus, results
might not generalize to patients with severe depression. Moreover,
participants had higher levels of education compared to a re-
presentative population-based sample with the same range of depres-
sive symptom severity (Späth et al., 2017). Therefore these results
might not generalize to all persons with mild to moderate depressive
symptoms. A final limitation is that participants were allocated to two
conditions, with the timing of access to the intervention representing a
confounder (immediate access in Deprexis vs. delayed access in CAU).
However, to analyze whether the observed differences for the three
depression groups are replicable among both conditions, separate
analysis for both groups were performed, which confirmed the findings
for the total sample.
4.2. Conclusions
We aimed to examine whether participants with ME and CD re-
semble each other closely, which might justify their inclusion in the
same diagnostic category. Our results provide concurrent (similar but
not identical baseline symptoms) and predictive validators (similar
three-year course) suggesting that patients with ME and CD belong to
the same category. More research is needed to elucidate whether ME
and CD should be included in a combined diagnostic category, as these
findings tentatively suggest.
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